@article{uoadl:3001627,
    volume = "29",
    number = "17",
    pages = "2323-2333",
    journal = "Ελληνικά Αρχεία AIDS=:  Hellenic Archives of AIDS",
    issn = "11058900",
    keywords = "abacavir;  nonnucleoside reverse transcriptase inhibitor;  proteinase inhibitor;  RNA directed DNA polymerase inhibitor;  tenofovir;  virus fusion inhibitor;  antiretrovirus agent, adult;  Article;  CD4 lymphocyte count;  disease course;  female;  highly active antiretroviral therapy;  human;  Human immunodeficiency virus 1;  Human immunodeficiency virus 1 infection;  major clinical study;  male;  odds ratio;  priority journal;  seroconversion;  virus inhibition;  CD4 lymphocyte count;  CD4+ T lymphocyte;  cohort analysis;  disease course;  HIV Infections;  immunology;  isolation and purification;  middle aged;  pathology;  time factor;  virus load;  young adult, Adult;  Anti-Retroviral Agents;  Antiretroviral Therapy, Highly Active;  CD4 Lymphocyte Count;  CD4-Positive T-Lymphocytes;  Cohort Studies;  Disease Progression;  Female;  HIV Infections;  HIV-1;  Humans;  Male;  Middle Aged;  Time Factors;  Viral Load;  Young Adult",
    BIBTEX_ENTRY = "article",
    year = "2015",
    author = "Jarrin, I. and Pantazis, N. and Dalmau, J. and Phillips, A.N. and Olson, A. and Mussini, C. and Boufassa, F. and Costagliola, D. and Porter, K. and Blanco, J. and Del Amo, J. and Martinez-Picado, J. and Chene, G. and Sabin, C. and Walker, S. and Fisher, M. and Kelleher, T. and Cooper, D. and Finlayson, R. and Bloch, M. and Ramacciotti, T. and Gelgor, L. and Smith, D. and Zangerle, R. and Gill, J. and Lutsar, I. and Dabis, F. and Thiebaut, R. and Guiguet, M. and Vanhems, P. and Chaix, M.-L. and Ghosn, J. and Meyer, L. and Hamouda, O. and Kucherer, C. and Bartmeyer, B. and Antoniadou, A. and Chrysos, G. and Daikos, G.L. and Touloumi, G. and Katsarou, O. and Rezza, G. and Dorrucci, M. and Monforte, A.D. and De Luca, A. and Prins, M. and Geskus, R. and Van Der Helm, J. and Schuitemaker, H. and Sannes, M. and Brubakk, O. and Kran, A.-M.B. and Rosinska, M. and Muga, R. and Tor, J. and De Olalla, P.G. and Cayla, J. and Moreno, S. and Monge, S. and Del Romero, J. and Perez-Hoyos, S. and Sonnerborg, A. and Bucher, H.C. and Gunthard, H. and Rickenbach, M. and Malyuta, R. and Murphy, G. and Johnson, A. and Babiker, A. and Pillay, D. and Morrison, C. and Salata, R. and Mugerwa, R. and Chipato, T. and Amornkul, P.N. and Gilmour, J. and Kamali, A. and Karita, E. and Burns, F. and Giaquinto, C. and Grarup, J. and Kirk, O. and Bailey, H. and Anne, A.V. and Panteleev, A. and Thorne, C. and Aboulker, J.-P. and Albert, J. and Asandi, S. and De Wit, S. and Reiss, P. and Gatell, J. and Karpov, I. and Ledergerber, B. and Lundgren, J. and Møller, C. and Rakhmanova, A. and Rockstroh, J. and Sandhu, M. and Dedes, N. and Fenton, K. and Pizzuti, D. and Vitoria, M. and Faggion, S. and Fradette, L. and Frost, R. and Cartier, A. and Raben, D. and Schwimmer, C. and Scott, M.",
    abstract = "Objective: This article compares trends in CD4 + T-cell recovery and proportions achieving optimal restoration (≥500cells/μl) after viral suppression following combination antiretroviral therapy (cART) initiation between rapid and nonrapid progressors. Methods: We included HIV-1 seroconverters achieving viral suppression within 6 months of cART. Rapid progressors were individuals experiencing at least one CD4 + less than 200cells/μl within 12 months of seroconverters before cART. We used piecewise linear mixed models and logistic regression for optimal restoration. Results: Of 4024 individuals, 294 (7.3%) were classified as rapid progressors. At the same CD4 + T-cell count at cART start (baseline), rapid progressors experienced faster CD4 + T-cell increases than nonrapid progressors in first month [difference (95% confidence interval) in mean increase/month (square root scale): 1.82 (1.61; 2.04)], which reversed to slightly slower increases in months 1-18 [-0.05 (-0.06; -0.03)] and no significant differences in 18-60 months [-0.003 (-0.01; 0.01)]. Percentage achieving optimal restoration was significantly lower for rapid progressors than nonrapid progressors at months 12 (29.2 vs. 62.5%) and 36 (47.1 vs. 72.4%) but not at month 60 (70.4 vs. 71.8%). These differences disappeared after adjusting for baseline CD4 + T-cell count: odds ratio (95% confidence interval) 0.86 (0.61; 1.20), 0.90 (0.38; 2.17) and 1.56 (0.55; 4.46) at months 12, 36 and 60, respectively. Conclusion: Among people on suppressive antiretroviral therapy, rapid progressors experience faster initial increases of CD4 + T-cell counts than nonrapid progressors, but are less likely to achieve optimal restoration during the first 36 months after cART, mainly because of lower CD4 + T-cell counts at cART initiation. Copyright © 2015 Wolters Kluwer Health, Inc. All rights reserved.",
    title = "Does rapid HIV disease progression prior to combination antiretroviral therapy hinder optimal CD4 + T-cell recovery once HIV-1 suppression is achieved?",
    doi = "10.1097/QAD.0000000000000805"
}